Sign In
Buy NAVB
$0.0001
+0 (+0%)
At Close: Dec 30, 2025
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
12:00am, Sunday, 10'th May 2020
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
Navidea Biopharmaceuticals to Host First Quarter 2020 Earnings Conference Call and Corporate Update
11:00am, Thursday, 07'th May 2020
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced i
Navidea Biopharmaceuticals Provides Statement Regarding COVID-19 Pandemic
11:30am, Wednesday, 22'nd Apr 2020
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announces the fol
What You Must Know About Navidea Biopharmaceuticals, Inc.'s (NYSEMKT:NAVB) Beta Value
12:52pm, Tuesday, 21'st Apr 2020
If you own shares in Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) then it's worth thinking about how it contributes...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced t
Edited Transcript of NAVB earnings conference call or presentation 11-Mar-20 9:00pm GMT
08:19pm, Tuesday, 24'th Mar 2020
Q4 2019 Navidea Biopharmaceuticals Inc Earnings Call
Navidea Biopharmaceuticals Announces Issuance of Patent Extension for Lymphoseek®
11:00am, Friday, 20'th Mar 2020
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced t
Navidea Biopharma Reports Issuance Of Patent Extension For Lymphoseek For Added 5 Years Through May 12, 2025
12:00am, Friday, 20'th Mar 2020Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
08:05pm, Wednesday, 11'th Mar 2020
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced i
Navidea Biopharmaceuticals, Inc. to Host Earnings Call
07:00pm, Wednesday, 11'th Mar 2020
NEW YORK, NY / ACCESSWIRE / March 11, 2020 / Navidea Biopharmaceuticals, Inc. (AMEX:NAVB) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 11, 2
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
12:03pm, Wednesday, 11'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu
Navidea Biopharmaceutical Q4 EPS $(0.15) Misses $(0.12) Estimate, Sales $119.299K Down From $119.321K YoY
12:00am, Wednesday, 11'th Mar 2020The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
08:14pm, Sunday, 08'th Mar 2020
Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
12:00am, Sunday, 08'th Mar 2020
Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
